News

The phase 3 ONCEMRK study, which is assessing Isentress in earlier untreated HIV-1 infected adults, met its primary efficacy endpoint by demonstrating that 1200mg of Isentress once-daily was

This announcement furthers the Company’s previously announced actions on October 22, 2015 to maximize efficiency and continue leveraging the strength of Perrigo’s global platform. A number of positions

Epilepsy is a brain disorder that causes people to have recurring seizures. A seizure is an episode, usually of relatively short duration, of abnormal brain activity. Seizures can

The FDA has extended the date for agency action by the standard period, from Feb. 27, 2016 to May 27, 2016. Following the Psychopharmacologic Advisory Committee meeting in

The trial is being performed under the direction of Drs. Filip Janku, M.D. and Gerald Falchook, M.D. as Co-Principal Investigators. Dr. Janku is Assistant Professor in the Department

Sectoral Asset Management and existing investors participated in the new funding round. In total, Effector has raised around $111m since its establishment in 2013. Effector’s lead compound is

In the phase III Ratify trial, patients who received PKC412 and chemotherapy experienced an increase in median overall survival compared to those receiving chemo alone (74.7 months versus

Under the trial, which is being undertaken in Stockholm, Sweden, two higher doses and volumes of BPZE1, 108 CFU and 109 CFU, will be studied as a follow-up

In the study, IW-1701 demonstrated the expected cardiovascular pharmacodynamic effects, proof of mechanism for sGC stimulation, a dose range that was well tolerated in healthy volunteers as a